SBIR Phase I: A knowledge base and drug repurposing platform for COVID-19

SBIR 第一阶段：COVID-19 知识库和药物再利用平台

• 批准号: 2029572
• 负责人: Cristiana IOSEF
• 金额: $ 25.6万
• 依托单位: Advaita Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2029572&HistoricalAwards=false
• 关键词: SBIR; Phase; knowledge; base; drug

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to create a software platform to facilitate the identification of existing drugs that can be re-purposed for other diseases, such as COVID-19. First, identifying FDA-approved drugs that could help COVID-19 patients is expected to save lives. Furthermore, this can prevent the economic consequences of extended or repeated mass quarantine episodes. Finally, the availability of a drug discovery platform for flu-like viruses that includes data from SARS-CoV-2 and other related viruses will add to the national cyberinfrastructure and will allow a better response at the next occurrence of a novel virus. The proposed project will develop a prototype platform to include: i) state-of-the-art data analysis methods, ii) a comprehensive knowledge base, and iii) an approach complementary to most other avenues currently pursued in the fight against COVID-19. The approach will focus on leveraging transcriptomics and other omics data focusing on the host’s immune response. This system will enable efficient research into issues such as the acute reaction of the immune systems, enabling approaches to mitigate and/or avoid a cytokine storm. This provides important information complementary to development of antiviral medications or vaccines, important for a future pandemic regardless of the virus strain.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响/商业潜力是创建一个软件平台，以促进识别可重新用于其他疾病（例如 COVID-19）的现有药物。 FDA 批准的药物有望帮助 COVID-19 患者挽救生命。此外，这可以防止长期或重复的大规模隔离事件造成的经济后果。最后，包含数据的流感样病毒药物发现平台的可用性。来自 SARS-CoV-2 和其他相关病毒将增加国家网络基础设施，并在下次出现新型病毒时能够做出更好的反应。拟议的项目将开发一个原型平台，其中包括：i）最先进的数据分析方法，ii）全面的知识。 iii) 与目前对抗 COVID-19 的大多数其他途径相补充的方法该方法将侧重于利用转录组学和其他关注宿主免疫反应的组学数据。急性的这为抗病毒药物或疫苗的开发提供了重要的补充信息，无论病毒株如何，对于未来的大流行都很重要。该奖项反映了 NSF 的法定使命，并具有重要意义。通过使用基金会的智力优点和更广泛的影响审查标准进行评估，被认为值得支持。